HRS9531 for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 May 2025: Trial registered, NCT06974851
  2. 25 Jul 2025: Trial started, NCT06974851

The trials

NCT06287437: HRS9531 Controls Weight Regain in Obese Subjects

State
State not given
Phase
Phase 2
People
72 planned
Started
1 Jan 2024
Primary completion
30 Jun 2025
Arms
Intervention
Results
None posted
  1. 1 Jan 2024: Trial started
  2. 1 Mar 2024: Trial registered

NCT06974851: A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

State
Under way
Phase
Phase 3
People
140 planned
Started
25 Jul 2025
Primary completion
Dec 2026
Arms
Group 1: HRS9531
Results
None posted
  1. 16 May 2025: Trial registered
  2. 25 Jul 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.